Cyclin A and β-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin

British Journal of Dermatology

Volumn 153, Issue 6, 2005, Pages 1166-1175

  Brasanac, Dimitrije ^a   Boricic, I ^a   Todorovic, V ^b   Tomanovic, N ^a   Radojevic, S ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Actinic keratosis; Bowen's disease; Cyclin A; Squamous cell carcinoma; catenin

Indexed keywords

BETA CATENIN; CYCLIN A;

ADULT; AGED; ARTICLE; BOWEN DISEASE; CELL DIFFERENTIATION; CELL LABELING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE CLASSIFICATION; FEMALE; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATOSIS; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

EID: 28844465802     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06898.x     Document Type: Article

References (72)

1. Bury J, Cross S. Molecular biology in diagnostic histopathology: part I-the cell cycle. Curr Diagn Pathol 2003; 9:266-75.
2. Sandal T. Molecular aspects of the mammalian cell cycle and cancer. Oncologist 2002; 7:73-81.
3. Brown DC, Gatter KC. K167 protein: the immaculate deception. Histopathology 2002; 40:2-11.
4. MacCallum DE, Hall PA. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol 2000; 190:537-44.
5. Yam CH, Fung TK, Poon RYC. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 2002; 59:1317-26.
6. Hsieh JK, Yap D, O'Connor DJ et al. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Bid 2002; 22:78-93.
7. Bukholm IRK, Bukholm G, Holm R, Nesland JM. Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas. J Clin Pathol 2003; 56:368-73.
8. Kuhling H, Alm P, Olsson H et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 2003; 199:424-31.
9. Saarilahti K, Kajanti M, Kouri M et al. Cyclin A and Ki67 expression as predictors for locoregional recurrence and outcome in laryngeal cancer patients treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57:986-95.
10. Volm M, Koomagi R, Mattern J, Efferth T. Expression profile of genes in non-small cell lung carcinomas from long term surviving patients. Clin Cancer Res 2002; 8:1843-8.
11. Dobashi Y, Jiang SX, Shoji M et al. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas. J Pathol 2003; 199:208-20.
12. Chen HM, Kuo MYP, Lin KH et al. Expression of cyclin A is related to progression of oral squamous cell carcinoma in Taiwan. Oral Oncol 2003; 39:476-82.
13. Nozoe T, Korenaga D, Futatsugi M et al. Cyclin A expression in superficial squamous cell carcinoma of the esophagus and coexisting infiltrated lymphocyte follicle. Cancer Lett 2002; 188:221-9.
14. Handa K, Yamakawa M, Takeda H et al. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999; 84:225-33.
15. Scott IS, Morris LS, Bird K et al. A novel immunohistochemical method to estimate cell cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J Pathol 2003; 201:187-97.
16. van de Putte G, Kristensen GB, Lie AK et al. Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol 2004; 92:40-6.
17. Kyushima N, Watanabe J, Hata H et al. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol 2002; 128:307-12.
18. Shih NC, Shiozawa T, Kato K et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 2003; 34:471-8.
19. Ito Y, Yoshida H, Nakano K et al. Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation. Pathol Res Pract 2002; 198:397-402.
20. Florenes VA, Maelandsmo GM, Faye R et al. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 2001; 195:530-6.
21. Georgieva J, Sinha P, Schadendorf D. Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol 2001; 54:229-35.
22. Tran TA, Ross JS, Carlson JA, Mihm MC. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum Pathol 1998; 29:1085-90.
23. Koljonen V, Tukiainen E, Haglund C, Bohling T. Expression of cyclin A in Merkel cell carcinoma. APMIS 2004; 112:39-44.
24. Tran TA, Ross JS, Boehm JR, Carlson JA. Comparison of mitotic cyclins and cyclin-dependent kinase expression in keratoacanthoma and squamous cell carcinoma. J Cutan Pathol 1999; 26:391-7.
25. Conacci-Sorrell M, Zhurinsky J, Ze'ev B. The cadherin-catenin adhesion system in signalling and cancer. J Clin Invest 2002; 109:987-91.
26. Behrens J. Control of β-catenin signaling in tumor development. Am NY Acad Sci 2000; 910:21-35.
27. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004; 303:1483-7.
28. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H et al. Expression patterns of β-catenin in in situ and invasive breast cancer. Eur J Surg Oncol 2001; 27:31-6.
29. Bankfalvi A, Terpe HJ, Breukelmann D et al. Immunophenotypic and prognostic analysis of E-cadherin and β-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopatholooy 1999; 34:25-34.
30. Pirinen RT, Hirvikoski P, Johansson RT et al. Reduced expression of α-catenin, β-catenin, and γ-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 2001; 54:391-5.
31. Yeh KT, Chang JG, Lin TH et al. Correlation between protein expression and epigenetic mutation changes of Wnt pathway-related genes in oral cancer. Int J Oncol 2003; 13:1001-7.
32. Sanders DSA, Bruton R, Darnton SJ et al. Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. Int J Cancer 1998; 79:573-9.
33. Ninomiya I, Endo Y, Fushida S et al. Alteration of β-catenin expression in esophageal squamous-cell carcinoma. Int J Cancer 2000; 8S:757-61.
34. Qiao Q, Ramadani M, Gansauge S et al. Reduced membranous and ectopic cytoplasmic expression of β-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 2001; 95:194-7.
35. Cui J, Zhou XD, Liu YK et al. Abnormal β-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China. World J Gastroenterol 2001; 7:542-6.
36. El-Bahrawy MA, Poulsom R, Jeffery R et al. The expression of E-cadherin and catenins in sporadic colorectal carcinoma. Hum Pathol 2001; 32:1216-24.
37. van de Putte G, Kristensen GB, Baekelandt M et al. E-cadherin and catenins in early squamous cervical carcinoma. Gynecol Oncol 2004; 94:521-7.
38. Omholt K, Platz A, Ringborg U, Hansson J. Cytoplasmic and nuclear accumulation of β-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer 2001; 92:839-42.
39. Krengel S, Groteluschen F, Bartsch S, Tronnier M. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocytic environment than on the tumor cell progression. J Cutan Pathol 2004; 31:1-7.
40. Demunter A, Libbrecht L, Degreef H et al. Loss of membranous expression of β-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod Pathol 2002; 15:454-61.
41. Kageshita T, Hamby CV, Ishihara T et al. Loss of β-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 2001; 145:210-16.
42. Maelandsmo GM, Holm R, Nesland JM et al. Reduced β-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 2003; 9:3383-8.
43. Moreno-Bueno G, Gamallo C, Perez-Gallego L et al. β-catenin expression in pilomatrixomas. Relationship with β-catenin gene mutations and comparison with β-catenin expression in normal hair follicles. Br J Dermatol 2001; 145:576-81.
44. Park SW, Suh KS, Wang HY et al. β-catenin expression in the transitional cell zone of pilomatricoma. Br J Dermatol 2001; 145:624-9.
45. El-Bahrawy M, El-Masry N, Alison M et al. Expression of β-catenin in basal cell carcinoma. Br J Dermatol 2003; 148:964-70.
46. Saldanha G, Ghura V, Potter L, Fletcher A. Nuclear β-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 2004; 151:157-64.
47. Papadavid E, Pignatelli M, Zakynthinos S et al. Abnormal immunoreactivity of the E-cadherin/catenin (α-, β- and γ-) complex in premalignant and malignant non-melanocytic skin tumours. J Pathol 2002; 196:154-62.
48. Lyakhovitsky A, Barzilai A, Fogel M et al. Expression of E-cadherin and β-catenin in cutaneous squamous cell carcinoma and its precursors. Am J Dermatopathol 2004; 26:372-8.
49. Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol 1997; 36:650-3.
50. Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in hyperkeratotic actinic keratosis. J Am Acad Dermatol 1997; 37:392-4.
51. Leffell DJ. Actinic keratoses: the scientific basis of skin cancer. J Am Acad Dermatol 2000; 42:518-22.
52. Lober BA, Lober CW. Actinic keratosis is squamous cell carcinoma. South Med J 2000; 93:650-5.
53. Heaphy MR, Ackerman AB. The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 2000; 43:138-50.
54. Person JR. An actinic keratosis is neither malignant nor premalignant: it is an initiated tumor. J Am Acad Dermatol 2003; 48:637-8.
55. Yantos VA, Conrad N, Zabawski E, Cockerell CJ. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg 1999; 18:3-14.
56. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ('actinic keratosis'). J Am Acad Dermatol 2000; 42:511-17.
57. Mortier L, Marchetti P, Delaporte E et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16INK4a tumor suppressor. Cancer Lett 2002; 176:205-14.
58. Blokx WAM, de Jong EMGJ, de Wilde PCM et al. p16 and p53 expression in (pre)malignant epidermal tumors of renal transplant recipients and immunocompetent individuals. Mod Pathol 2003; 16:869-78.
59. Evans C, Cockerell CJ. Actinic keratosis: time to call a spade a spade. South Med J 2000; 93:734-6.
60. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37:677-81.
61. Guenthner ST, Hurwitz RM, Buckell LJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathological correlation. J Am Acad Dermatol 1999; 41:443-8.
62. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:58-10.
63. Fu W, Cockerell CJ. The actinic (solar) keratosis. A 21st-century perspective. Arch Dermatol 2003; 139:66-70.
64. Ortonne JP. From actinic keratosis to squamous cell carcinoma. Br J Dermatol 2002; 146 (Suppl. 61):20-3.
65. Hodges A, Smoller BR. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin. Mod Pathol 2002; 15:1121-5.
66. Salama ME, Mahmood MN, Qureshi HS et al. p16INK4a expression in actinic keratosis and Bowen's disease. Br J Dermatol 2003; 149:1006-12.
67. Oh CW, Penneys N. P27 and Mib1 expression in actinic keratosis, Bowen's disease, and squamous cell carcinoma. Am J Dermatopathol 2004; 26:22-6.
68. Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Plast Surg 2003; 56:85-91.
69. Chasle J, Delozier T, Denoux Y et al. Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas-a preliminary study. Eur J Cancer 2003; 39:1363-9.
70. Doglioni C, Piccinin S, Demontis S et al. Alterations of β-catenin pathway in non-melanoma skin tumors. Loss of α-ABC nuclear reactivity correlates with the presence of β-catenin gene mutation. Am J Pathol 2003; 163:2277-87.
71. Bukholm IR, Bukholm G, Nesland JM. Coexpression of cyclin A and β-catenin and survival in breast cancer patients. Int J Cancer 2001; 94:148-9.
72. Kim SI, Park CS, Lee MS et al. Cyclin-dependent kinase 2 regulates the interaction of Axin with β-catenin. Biochem Biophys Res Commun 2004; 317:478-83.